Phillips-Medisize Corporation

Phillips-Medisize Corporation

44 Follower

>5.000 Mitarbeitende

Neuigkeiten

Alle Neuigkeiten

Phillips-Medisize Corporationhat einen Beitrag geschrieben.25. Juli 2018

Building on a scalable technology that benefits pharma clients and their providers and patients Hudson, WI – Tuesday, July 24, 2018 – Phillips-Medisize, a Molex company, announced the release of its third generation connected health platform, a service offering for its pharma and drug delivery device clients. The platform builds on the success of the company’s first connected health solutions, including the first FDA-approved combination product for medication adherence, and incorporates more...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.17. Mai 2018

New Suzhou facility quadruples manufacturing space, deepens commitment to Asia for Asia strategy HUDSON, WI – May 17, 2018 – phillipsmedisize – Phillips-Medisize, a Molex company, has announced a significant company expansion in Suzhou, China. The company has added approximately 140,000 sq. ft. (13,000 sq. m.) of medical manufacturing space near the company’s existing site, expanding not only the company’s manufacturing abilities and capacity in China, but also the design and development serv...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.15. Mai 2018

HUDSON, WI – May 15, 2018 – phillipsmedisize – Phillips-Medisize will showcase its solutions for design development and manufacturing of drug delivery devices, with a focus on connected health, for the first time during Innopack Pharma Confex India. The wide variety of contract services featured include device strategy, product development and manufacturing across specialty drug delivery devices, disposable insulin pens, blood glucose meters, inhalators, and wearable drug delivery devices des...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.1. Mai 2018

HUDSON, WI – May 1, 2018 – phillipsmedisize – Phillips-Medisize, a Molex company, has announced the completion of another significant expansion to the company’s New Richmond, Wisconsin medical facility. With this expansion, the New Richmond site will bring value-added capabilities in drug handling to serve its pharmaceutical customers with the complete manufacture of drug delivery devices and compliance to the FDA 21 CFR 210/211 requirements. The New Richmond facility will add nearly 70,000 s...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.20. April 2018

HUDSON, WI – April 20, 2018 – phillipsmedisize.com – Phillips-Medisize is a sponsor and exhibitor at this year’s Respiratory Drug Delivery (RDD) conference in Tucson, AZ on April 22-26. RDD offers attendees the unique opportunity to participate in one of the premier international conferences in respiratory drug delivery. Delivering Connected Health solutions, at scale, isn’t easy. Phillips-Medisize, through its Medicom subsidiary, developed the first FDA approved Connected Health system for a...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.13. April 2018

HUDSON, WI – April 13, 2018 – phillipsmedisize – Phillips-Medisize, a Molex company, will be part of Medtec Europe in Stuttgart, Germany on April 17-19. A key element of Medtec Europe 2018 will be Smart Health and Technology Innovations. The competitive landscape in the medical technology industry continues to change through new production technologies and connected health solutions; the industry is developing a need for digitization and smart solutions throughout all segments of medical devi...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.6. Dezember 2017

HUDSON, WI – December 6, 2017 – phillipsmedisize – Phillips-Medisize, a Molex company, announces its initial investment to expand the capabilities of the 380,000 square foot Molex Little Rock facility to include a FDA registered manufacturing Center of Excellence for Connected Health and drug delivery devices. The construction of purpose-built clean room suites, as well as FDA registration and ISO 13485 certification are scheduled to be complete for its first customer’s production beginning i...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.4. Dezember 2017

San Francisco, California, December 4, 2017 – Dance Biopharm Holdings Inc. (“Dance”), a privately-held biotechnology company focused on the development of Dance 501, a proprietary ‘soft-mist’ inhaled insulin product to treat diabetes, is pleased to announce that Dance has entered into a joint development agreement (JDA) with Phillips-Medisize, LLC, a subsidiary of Molex Electronic Technologies, LLC, a leader in electronic solutions, to develop a version of the Dance 501 device that has data conn...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.2. November 2017

HUDSON, WI - November 2, 2017 – phillipsmedisize - Phillips-Medisize, a Molex company, will participate at the 14th Parental Drug Association (PDA) Universe of Pre-filled Syringes and Injection Devices Conference and Exhibition in the Austria Center in Vienna on 7-8 November 2017. Phillips-Medisize has a stand (X68/69) in the exhibition area at the PDA event. Bjørn Knud Andersen, from Medicom Innovation Partner, a subsidiary of Phillips-Medisize, will present a conference paper at 17:45 hours on...

Phillips-Medisize Corporationhat einen Beitrag geschrieben.19. Oktober 2017

Hudson, WI – October 19, 2017 – Phillips-Medisize, LLC will present solutions for development and manufacture of drug delivery devices and primary pharmaceutical packaging, with a particular focus on connected health solutions where devices, connected services and drugs are completely integrated... http://bit.ly/2xRR6cS

Alle Neuigkeiten

XING empfiehlt folgende Unternehmen:

ProBioGen AG

ABF

Dr. Reckeweg & Co. GmbH

Über uns

Alle Infos ansehen

Phillips-Medisize is a leading global outsource provider of design and manufacturing services to the medical (medical device, diagnostics, and drug delivery products) and commercial (automotive, consumer, and defense) markets. The company has annual sales of just under $500 million with 75% of the total revenue coming from...

Alle Infos ansehen